(11/1/17) Update: Despite the growing body of scientific evidence showing that cannabis access is associated with reductions in opioid use and mortality, Governor Chris Christie (R-NJ), who serves as Chairman of the White House’s Commission on Combating Drug Addiction and the Opioid Crisis called upon the President to reject any efforts to acknowledge marijuana’s promising role in mitigating opioid abuse and dependency.

The Office of National Drug Control Policy (ONDCP) has issued the initial recommendations for President Trump’s Commission on Combating Drug Addiction and the Opioid Crisis without referencing medical cannabis, regardless of the recent evidence that suggests increased access to medical cannabis is associated with reduced rates of opioid use and abuse, opioid-related hospitalizations, opioid-related traffic fatalities, opioid-related drug treatment admissions, and opioid-related overdose deaths.

In a widely publicized study, researchers with the Journal of the American Medical Association determined that, “States with medical cannabis laws had a 24.8 percent lower mean annual opioid overdose mortality rate compared with states without medical cannabis laws.” A similar review by investigators at the RAND Corporation determined, “tates permitting medical marijuana dispensaries experience a relative decrease in both opioid addictions and opioid overdose deaths compared to states that do not.”

Click the link below to send a letter to the ONDCP Commission to educate them about the positive role that medical cannabis can play in curtailing opioid abuse in America!

Send a letter to the ONDCP Commission

Contact the ONDCP Commission: Medical Marijuana as an Alternative to Opioids